Please use this identifier to cite or link to this item: http://buratest.brunel.ac.uk/handle/2438/10426
Title: How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy and practice
Authors: Hanney, SR
Castle-Clarke, S
Grant, J
Guthrie, S
Henshall, C
Mestre-Ferrandiz, J
Pistollato, M
Pollitt, A
Sussex, J
Wooding, S
Keywords: Basic research;Clinical guidelines;Discovery research;Economic impact of research;Human research;Pharmaceutical industry;Process marker model;Regulatory approval;Time lags;Timelines
Issue Date: 2015
Publisher: BioMed Central
Citation: Health Research Policy and Systems, 2015, 13 (1)
Abstract: Background: The time taken, or ‘time lags’, between biomedical/health research and its translation into health improvements is receiving growing attention. Reducing time lags should increase rates of return to such research. However, ways to measure time lags are under-developed, with little attention on where time lags arise within overall timelines. The process marker model has been proposed as a better way forward than the current focus on an increasingly complex series of translation ‘gaps’. Starting from that model, we aimed to develop better methods to measure and understand time lags and develop ways to identify policy options and produce recommendations for future studies. Methods: Following reviews of the literature on time lags and of relevant policy documents, we developed a new approach to conduct case studies of time lags. We built on the process marker model, including developing a matrix with a series of overlapping tracks to allow us to present and measure elements within any overall time lag. We identified a reduced number of key markers or calibration points and tested our new approach in seven case studies of research leading to interventions in cardiovascular disease and mental health. Finally, we analysed the data to address our study’s key aims. Results: The literature review illustrated the lack of agreement on starting points for measuring time lags. We mapped points from policy documents onto our matrix and thus highlighted key areas of concern, for example around delays before new therapies become widely available. Our seven completed case studies demonstrate we have made considerable progress in developing methods to measure and understand time lags. The matrix of overlapping tracks of activity in the research and implementation processes facilitated analysis of time lags along each track, and at the cross-over points where the next track started. We identified some factors that speed up translation through the actions of companies, researchers, funders, policymakers, and regulators. Recommendations for further work are built on progress made, limitations identified and revised terminology. Conclusions: Our advances identify complexities, provide a firm basis for further methodological work along and between tracks, and begin to indicate potential ways of reducing lags.
Description: This article has been made available through the Brunel Open Access Publishing Fund.
URI: http://bura.brunel.ac.uk/handle/2438/10426
DOI: http://dx.doi.org/10.1186/1478-4505-13-1
ISSN: 1478-4505
Appears in Collections:Brunel OA Publishing Fund
Health Economics Research Group (HERG)
Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf1.66 MBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.